Abstract
The immune system has demonstrated the ability to participate in cancer surveillance, but its role in promoting anticancer activity has only begun to be harnessed. Advances over the last 10 years have made the possibility of immunotherapy for the treatment of cancer a more realistic possibility. Prostate cancer is an ideal target for immunotherapy given its relatively slow growth rate and the time required to generate immune responses. This chapter will discuss an antibody to cytotoxic T lymphocyte antigen-4 (CTLA-4), which can dampen the restraints on T-cell activity to incite a T cell response to tumor, resulting in immune-mediated tumor regression, and the experience with this mechanism in treating advanced prostate cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frauwirth KA, Thompson, CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109(3):295–9.
Chambers C, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565–94.
Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4(5):336–47.
Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006;24(5):442–7.
Waterhouse P, Penninger JM, Timms E, Wakeham A. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270(5238):985–8.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541–7.
Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 1999;189(2):435–40.
Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997;94(15):8099–103.
Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999;96(26):15074–9.
Small EJ, Tchekmedyian NS, Rini B, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810–5.
Hurwitz AA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444–8.
Fong L, et al. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007;25(18S):3001.
Gerritsen W, van den Eertwegh AJ, T. de Gruijl T, et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). Proc Am Soc Clin Oncol 2008:Abstr 5146.
Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8(19):1765–80.
Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26(305):234–41.
Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58(3):862–70.
Demaria S, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11(2 Pt 1):728–34.
Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol 2008:Abstr 5004.
Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23(25):6043–53.
Fasso M, Waitz R, Hou Y, et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A 2008;105(9):3509–14.
Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67(18):8900–5.
Imai H, Saio M, Nonaka K, et al. Depletion of CD4+ CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007;98(3):416–23.
Tuve S, Chen B-M, Liu Y, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67(12):5929–39.
Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112(3):610–8.
Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623–33.
Ghiringhelli F, Menard C, PE Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641–8.
Kavanagh B, O’Brien S, Lee D, et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008;112(4):1175–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Harzstark, A.L., Fong, L. (2010). CTLA-4 Blockade for Prostate Cancer Treatment. In: Figg, W., Chau, C., Small, E. (eds) Drug Management of Prostate Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-829-4_30
Download citation
DOI: https://doi.org/10.1007/978-1-60327-829-4_30
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-60327-831-7
Online ISBN: 978-1-60327-829-4
eBook Packages: MedicineMedicine (R0)